SCHEMBL5026352

SCHEMBL5026352

O=C(Cc1cccnc1)Nc1cc(-c2ccccn2)nc(-c2ncco2)n1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 6/20 0.43
MKNK1 Q9BUB5 1/20 0.43
WNT3A P56704 6/20 0.42
CDK9 P50750 1/20 0.42
WNT1 P04628 1/20 0.41
GSK3B P49841 1/20 0.41
DYRK1A Q13627 1/20 0.41
CYP3A4 P08684 3/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
ADORA1 P30542 1/20 0.40
GLS O94925 3/20 0.40
KDM4E B2RXH2 1/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
ESR1 P03372 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5024997 0.88 ADORA2A (0.53) ADORA2AMKNK1WNT3ACDK9WNT1
SCHEMBL5016080 0.86 ADORA2A (0.53) ADORA2AMKNK1WNT3ACDK9WNT1
SCHEMBL5017837 0.84 ADORA2A (0.51) ADORA2ACDK9ADORA1GLS
SCHEMBL5026311 0.82 ADORA2A (0.61) ADORA2AMKNK1WNT3ACDK9WNT1
SCHEMBL5017601 0.81 ADORA2A (0.52) ADORA2AMKNK1WNT1GSK3BDYRK1A
SCHEMBL5016157 0.81 ADORA2A (0.61) ADORA2AWNT3ACDK9ADORA1GLS
SCHEMBL5022393 0.80 ADORA2A (0.46) ADORA2AMKNK1ADORA1
SCHEMBL5022860 0.80 ADORA2A (0.51) ADORA2AMKNK1CDK9WNT1GSK3B
SCHEMBL5022900 0.78 ADORA2A (0.54) ADORA2AWNT3ACYP3A4ADORA1GLS
SCHEMBL5026329 0.78 ADORA2A (0.58) ADORA2ACYP3A4ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists NEUROCRINE BIOSCIENCES, INC. (US) 2008-03-06 US disclosed
EP-1697351-A1 2,6-BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS Almirall Prodesfarma AG (CH) 2006-09-06 EP disclosed
WO-2005058883-A1 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL PRODESFARMA AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058356-A1 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885MKNK1 3055/4885WNT3A 951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.